Key facts
- Slate Bio’s last known valuation is $11.3M (May 2023).
- It has raised $6.0M across 2 recorded rounds; the latest was Seed Round ($2.8M) in Dec 2022.
- Notable investors include Virginia Innovation Partnership Corporation, Virginia Venture Partners, CAV Angels, University of Virginia, Epidarex Capital — 8 tracked in total.
- Slate Bio has filed 3 Form Ds with the SEC since 2021, most recently May 2023 ($2.8M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Slate Bio
Funding rounds
2 roundsAbout Slate Bio
Developer of a therapeutic platform intended to offer immunotherapeutics to resist autoimmune and inflammatory diseases. The company creates therapies that restore the body's natural immunological response in various diseases using bifunctional cytokines, enabling patients a second independent synergistic pathway that has tissue selectivity and improved pharmacodynamics, at lower doses and without side effects.
- Sector
- Healthcare
- HQ
- Charlottesville, VA, United States
- Founded
- 2020
- Employees
- 5
- Website
- slatebio.com/
- Ownership
- Privately Held (backing)
Slate Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Slate Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Slate Bio in its N-PORT filings yet. We sweep new filings monthly.